Keyphrases
Acute Myeloid Leukemia
100%
Leukemia Patients
50%
Chronic Lymphocytic Leukemia
31%
Bone Marrow
29%
Minimal Residual Disease
27%
De Novo Acute Myeloid Leukemia
27%
Overall Survival
27%
Annualized Relapse Rate
20%
Intermediate Cytogenetic Risk
19%
Diffuse Large B-cell Lymphoma (DLBCL)
18%
Prognostic Value
17%
Intermediate-risk Acute Myeloid Leukemia
16%
Quantitative PCR
16%
Leukemia-free Survival
15%
FMS-like Tyrosine Kinase 3 (FLT3)
14%
Prognostic Significance
14%
Prognostic Marker
13%
Acute Lymphoblastic Leukemia
13%
Acute Promyelocytic Leukemia
12%
Gene Expression
12%
Adult Patients
12%
Multivariate Analysis
12%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
12%
Post-remission Therapy
12%
BCP-ALL
12%
Core Binding Factor Leukemia
12%
Molecular Findings
12%
Inv(16)
12%
Microsatellite Instability-high (MSI-H)
12%
Ayahuasca
12%
CD34
11%
BAALC
11%
Adult Acute Lymphoblastic Leukemia
11%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
10%
Poor Prognosis
9%
Copy number Variation
9%
NPM1 mutation
9%
Hazard Ratio
9%
Independent Prognostic Factor
9%
Genetic Analysis
9%
Prognostic Factors
8%
Expression Level
8%
Hematopoietic Stem Cell Transplantation
8%
Molecular Characterization
8%
Molecular Profiling
8%
Normal Karyotype
8%
Elderly Patients
8%
Molecular Study
8%
MicroRNA Signature
8%
High-level Expression
8%
Medicine and Dentistry
Acute Myeloid Leukemia
79%
B-Cell Chronic Lymphocytic Leukemia
31%
Overall Survival
29%
Minimal Residual Disease
26%
Acute Lymphoblastic Leukemia
25%
Cumulative Incidence
22%
B Cell
21%
Precursor
20%
De Novo Acute Myeloid Leukemia
19%
Leukocyte
15%
Gene Expression
13%
microRNA
13%
Multivariate Analysis
13%
Flow Cytometry
13%
Acute Promyelocytic Leukemia
12%
Prognostic Factor
12%
Leukemia
12%
Diffuse Large B-Cell Lymphoma
12%
Core Binding Factor
12%
Chemotherapy
10%
Diseases
9%
Karyotype
9%
Biological Product
9%
Allogeneic Hematopoietic Stem Cell Transplantation
9%
Myelodysplastic Syndrome
8%
Messenger RNA
8%
Neoplasm
8%
Beta 2 Microglobulin
7%
Anthracycline
7%
Single Nucleotide Polymorphism
7%
Recurrence Risk
7%
Chronic Lymphocytic Leukemia
7%
Molecular Profiling
7%
Hematopoietic Stem Cell Transplantation
7%
Philadelphia 1 Chromosome
7%
Elderly Patient
7%
Adolescence
7%
Fluorescence in Situ Hybridization
7%
CD2 Antigen
7%
Gene Expression Profiling
7%
NPM1
6%
Tretinoin
6%
Immunophenotyping
6%
Azacitidine
6%
Monosomy
6%
Mortality Rate
6%
Prognostic Signature
6%
Platelet
6%
Prognostic Assessment
6%
Mast Cell Leukemia
6%
Biochemistry, Genetics and Molecular Biology
Myeloid
84%
B Cell
36%
Genetics
32%
Cytogenetics
30%
Precursor
20%
Overall Survival
17%
Gene Expression
14%
Genomics
13%
MicroRNA
13%
Microsatellite Instability
12%
Core Binding Factor
12%
Fluorescence in Situ Hybridization
11%
Leukocyte Count
10%
NPM1
9%
Gene Deletion
9%
Adolescence
9%
Karyotype
8%
Philadelphia Chromosome
8%
Beta-2 Microglobulin
8%
Multivariate Analysis
7%
Interphase
7%
Gene Expression Profiling
7%
E-Box
6%
Transcription
6%
Cyclin-Dependent Kinase
6%
Dysplasia
6%
Uniparental Disomy
6%
CDKN2B
6%
Exon
6%
Focal Adhesion
6%
Long Non-Coding RNA
6%
CD200
6%
PTK2B
6%
LYN
6%
T Cell
6%
Genetic Susceptibility
6%
Trisomy
6%
Peripheral Blood Cell
6%
PTPN11
6%
Stromal Cell
6%
Glomerulus Filtration
6%
Vascular Endothelial Growth Factor C
6%
N,N-Dimethyltryptamine
6%
Normal Human
6%
Epigenetics
6%
Cellular Immunity
6%
Lymphocyte Subpopulation
6%
Clinical Trial
6%
Monoamine Oxidase
6%
Monoamine Oxidase A
6%